There is reduction in pro-inflammatory markers like hsCRP, IL-6, IL-1β, TNF-α, and IFN-γ in patients with diabetes and in vitro models without diabetes, while there is a change in polarity from M1 to M2 macrophages when treated with SGLT2i [11,20,21,22,23,24,25]. This evidence concerns the gene IL6 and diabetes mellitus.